Paraproteinaemias: pathophysiology
- PMID: 11103434
Paraproteinaemias: pathophysiology
Abstract
Paraproteinaemias may be associated with benign or malignant proliferations of lymphocytes or plasma cells, including multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS) and Waldenström's macroglobulinaemia. Primary amyloidosis may be associated with multiple myeloma and rarely with lymphoid malignancies, but most cases can be considered as a particular form of monoclonal gammopathy of undetermined significance, where the paraprotein causes damage by virtue of its amyloidogenic properties. This article discusses recent advances in understanding of the biology of multiple myeloma. Multiple myeloma is now known to arise from a post-germinal centre B cell in the lymph node which homes to the bone marrow. Interactions with stromal cells in the marrow facilitate homing and growth of the myeloma cells. The stromal cells produce IL-6, which is an important growth factor for myeloma cells, while the myeloma cells produce factors such as TNF-alpha and IL-1 beta that activate osteoclasts, resulting in myeloma bone disease. Myeloma cells also produce vascular endothelial growth factor which results in increased microvessel formation in the marrow, promoting tumour growth. There has been interest in the possible role of the Kaposi's sarcoma associated herpes virus (HHV8) in multiple myeloma, following the demonstration of viral gene sequences in multiple myeloma marrow. However, results of further studies have been conflicting and at present there is no clear evidence for an aetiological role of HHV8 in multiple myeloma. Cytogenetic studies using modern techniques have demonstrated that almost all multiple myeloma cases are cytogenetically abnormal, the predominant abnormalities being various translocations involving chromosome 14q and deletions of chromosome 13. 14q translocations are equally common in monoclonal gammopathy of undetermined significance, but deletions of chromosome 13 seem to be associated with progression to multiple myeloma, and also have powerful prognostic significance for survival in multiple myeloma patients.
Similar articles
-
Role of cytokines in multiple myeloma.Semin Hematol. 1999 Jan;36(1 Suppl 3):14-20. Semin Hematol. 1999. PMID: 9989484 Review.
-
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.Clin Cancer Res. 2002 Jul;8(7):2210-6. Clin Cancer Res. 2002. PMID: 12114422
-
New insights in the clinical biology of multiple myeloma.Semin Hematol. 1997 Jan;34(1 Suppl 1):23-8. Semin Hematol. 1997. PMID: 9122743 Review.
-
14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.Cancer Res. 1999 Sep 15;59(18):4546-50. Cancer Res. 1999. PMID: 10493504
-
Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.Cancer. 2003 Feb 1;97(3):601-9. doi: 10.1002/cncr.11100. Cancer. 2003. PMID: 12548602
Cited by
-
Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.Blood. 2008 Apr 1;111(7):3388-94. doi: 10.1182/blood-2007-10-121285. Epub 2008 Jan 31. Blood. 2008. PMID: 18239085 Free PMC article.